

# Tourette Syndrome Therapeutic and Drug Pipeline Review H2

*Tourette Syndrome Therapeutic and Drug Pipeline Review H2*

PUNE, INDIA, March 17, 2017  
/EINPresswire.com/ -- [Tourette Syndrome](#) - Pipeline Review, H1 2017

## Summary

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the

nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/1056668-tourette-syndrome-pipeline-review-h1-2017>

## Report Highlights

This report provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Unknown stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

## Scope



- The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

#### Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

#### Table of Content: Key Points

List of Tables

List of Figures

Introduction

Tourette Syndrome - Overview

Tourette Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tourette Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tourette Syndrome - Companies Involved in Therapeutics Development

Catalyst Pharmaceuticals Inc

Neurocrine Biosciences Inc

Psyadon Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Synchroneuron Inc

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Tourette Syndrome - Drug Profiles

(amfetamine + guanfacine hydrochloride) - Drug Profile

...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/1056668-tourette-syndrome-pipeline-review-h1-2017>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.